Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

2021 ISGIO Meeting Packed With Multidisciplinary Updates in Gastrointestinal Cancers

November 9th 2021

Gastrointestinal cancer is increasingly viewed through a multidisciplinary lens, and the 2021 International Society of Gastrointestinal Oncology Annual Meeting produced intriguing developments in the armamentarium.

Dr. Marshall on the Potential Utility of Trastuzumab Deruxtecan in HER2+ Gastric Cancer

November 8th 2021

John L. Marshall, MD, discusses the potential utility of trastuzumab deruxtecan in HER2-positive gastric cancer.

Yarchoan Talks Research Directions in Fibrolamellar Carcinoma

November 4th 2021

Dr. Yarchoan underscores the unique characteristics of fibrolamellar carcinoma, treatment options for these patients, and ongoing research efforts to expand the limited paradigm in this disease.

Infigratinib Shows Promising Early Activity in FGFR2-Altered Cholangiocarcinoma

November 1st 2021

The FGFR inhibitor infigratinib demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or rearrangement.

Pancreatic Cancer Incidence Rises, Notably Among Younger Women

October 31st 2021

Incidence of pancreatic cancer incidence rose overall from 2000 to 2018, with a significant increase in women younger than 55 years, especially those aged 15 to 35 years.

Jain and Spaggiari Speak to Surgical and Systemic Considerations for CRC Liver Metastases

October 28th 2021

Dr. Jain and Dr. Spaggiari highlight key advancements in the treatment of patients with colorectal cancer liver metastases, patient and disease factors to consider during surgical and systemic treatment decisions, and the importance of multidisciplinary care in this patient population.

Dr. Ku on Evaluating Zanidatamab Plus Chemotherapy in HER2-Expressing GEA

October 27th 2021

Geoffrey Y. Ku, MD, discusses the rationale to evaluate zanidatamab in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.

Dr. Shroff on Unmet Needs in Advanced Biliary Tract Cancer

October 26th 2021

Rachna T. Shroff, MD, MS, discusses unmet needs in advanced biliary tract cancer.

Dr. Catenacci on Navigating HER2 Testing in Gastric/GEJ Cancer

October 25th 2021

Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.

Dr. Heimbach on the Need for Multidisciplinary Care in HCC

October 25th 2021

Julie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.

Dr. Marshall on the Results of the DESTINY-Gastric02 Trial in Gastric/GEJ Cancer

October 25th 2021

John L. Marshall, MD, discusses the results of the phase 2 DESTINY-Gastric02 trial in HER2-positive gastric and gastroesophageal junction cancers.

Eryaspase/Chemo Misses OS End Point in Second-Line Pancreatic Cancer, But Warrants Further Investigation

October 25th 2021

Although the addition of eryaspase to chemotherapy improved overall survival over chemotherapy alone in patients with metastatic pancreatic cancer, the difference in benefit was not found to be statistically significant, missing the primary end point of the phase 3 TRYbeCA-1 trial.

Durvalumab Plus Chemo Significantly Improves OS in Frontline Advanced Biliary Tract Cancer

October 25th 2021

The combination of durvalumab and chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone when used in the first-line treatment of patients with advanced biliary tract cancer, meeting the primary end point of the phase 3 TOPAZ-1 trial.

Dr. Yarchoan on Unique Characteristics of Fibrolamellar Carcinoma

October 22nd 2021

Mark Yarchoan, MD, discusses unique characteristics of fibrolamellar carcinoma.

Dr. Shroff on the Importance of Targeted Therapy in Advanced Biliary Tract Cancer

October 21st 2021

Rachna T. Shroff, MD, discusses the importance of targeted therapy in advanced biliary tract cancer.

Dr. Zalcberg on the Rationale for Dose Escalation With Ripretinib in Advanced GIST

October 21st 2021

John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Dr. Zhen on the Need for Novel Therapies in Poorly Differentiated Small-Cell-Type NETs

October 21st 2021

David Zhen, MD, discusses the need for novel therapies in poorly differentiated small-cell-type neuroendocrine tumors.

Nivolumab/Chemo Approved in Europe for HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

October 21st 2021

The European Commission has approved nivolumab plus fluoropyrimidine- and platinum-based chemotherapy for the frontline treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma whose tumors have a PD-L1 combined positive score of 5 or higher.

Lessons Learned May Hold the Key for Improving Outcomes in Fibrolamellar Carcinoma

October 21st 2021

Fibrolamellar carcinoma is an extremely rare form of liver cancer that affects approximately 1 in 5 million Americans. However, because the disease appears so infrequently, it may be underdiagnosed.

Dr. Soares on Advances in the Management of Pancreatic NETs

October 19th 2021

Heloisa P. Soares, MD, PhD, discusses advances in the management of pancreatic neuroendocrine tumors.